Akums Drugs & Pharmaceuticals has secured a patent for its Benzalkonium Chloride-Free Brinzolamide Ophthalmic Formulation, designed for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The patent is valid for a term of 20 years.
In India, glaucoma affects approximately 11.9 million people, contributing to 12.8% of blindness cases. Among adults aged 40 years and above, the prevalence of glaucoma ranges from 2.7% to 4.3%. Addressing this critical ophthalmic challenge, Benzalkonium Chloride-Free Brinzolamide Ophthalmic Formulation offers a key advantage over traditional eye drops containing preservatives like benzalkonium chloride, which can cause ocular surface irritation, dryness, and discomfort with prolonged use. By eliminating Benzalkonium Chloride, this innovative formulation enhances patient comfort, making it particularly beneficial for individuals those requiring long-term glaucoma management.
Akums Drugs and Pharmaceuticals is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services in India and overseas.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1766.00 |
Dr. Reddys Lab | 1180.55 |
Cipla | 1510.65 |
Lupin | 2068.70 |
Zydus Lifesciences | 907.45 |
View more.. |